A Randomized, Double- Blind, Placebo-Controlled, Phase Study to Assess the Efficacy and Safety of 2/3 Setrusumab in Subjects with Osteogenesis Imperfecta

Title

Code

UX143- CL301

Type

Sperimentale con farmaco

Start Year

2023

Status

In Corso

Principal Investigator

051-6366519, 051-6366681

luca.sangiorgi@ior.it

Sangiorgi Luca, MD

Director

Rare skeletal disorders

Operational unit that carry out the study

complex unit

Malattie rare scheletriche

Director

Sangiorgi Luca, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. UX143-CL301

Tuesday 9 May 2023, 16:11

PG0007204_2023_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

A Randomized, Double- Blind, Placebo-Controlled, Phase Study to Assess the Efficacy and Safety of 2/3 Setrusumab in Subjects with Osteogenesis Imperfecta

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

A Randomized, Double- Blind, Placebo-Controlled, Phase Study to Assess the Efficacy and Safety of 2/3 Setrusumab in Subjects with Osteogenesis Imperfecta

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in